- Home
- OI vs SLNO Comparison
OI vs SLNO Comparison
Compare OI & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | SLNO |
|---|---|---|
| Founded | 1903 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.3B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OI | SLNO |
|---|---|---|
| Price | $9.15 | $53.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $15.29 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.59 |
| Revenue | ★ $6,426,000,000.00 | $1,450,788.00 |
| Revenue This Year | $2.77 | $150.46 |
| Revenue Next Year | $1.88 | $50.37 |
| P/E Ratio | ★ N/A | $89.83 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $7.75 | $29.43 |
| 52 Week High | $16.91 | $89.12 |
Technical Indicators
Market Signals| Indicator | OI | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 77.32 |
| Support Level | $8.07 | $48.91 |
| Resistance Level | $9.36 | $55.47 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | 0.13 | -0.52 |
| Stochastic Oscillator | 87.58 | 100.00 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.